Plerixafor added to G-CSF allows mobilization of a sufficient number of hematopoietic progenitors without impacting the efficacy of TCR-alpha/beta depletion in pediatric haploidentical and genoidentical donors failing to mobilize with G-CSF alone.
J Clin Apher
; 36(4): 547-552, 2021 Aug.
Article
em En
| MEDLINE
| ID: mdl-33682959
ABSTRACT
BACKGROUND:
Collection of a large number of early hematopoietic progenitors is essential for allogeneic apheresis products intended for TCR-alpha/beta depletion. MATERIALS ANDMETHODS:
We added plerixafor 0.24 mg/kg body weight (bw) on day 4 of high-dose filgrastim mobilization 10 hours prior to apheresis in 16 (30.5%) pediatric allogeneic donors who failed to recover a sufficient number of CD34+ cells.RESULTS:
On day 4 of G-CSF, the median CD34+ cell count in peripheral blood was 6 per µL (range 4-9 per µL) in 6 poor mobilizers and 16 per µL (range 12-19 per µL) in insufficient mobilizers. In all donors, the threshold of 50 CD34+ cells/µL was achieved, and the median increase was 14.8-fold in poor mobilizers and 6.5-fold in insufficient mobilizers, whereas it was 3.45-fold increase in those mobilized with G-CSF alone.DISCUSSION:
In all donors, a predefined number of >10 × 106 CD34+ cells/kg of recipient bw before depletion was reached in the apheresis product. The use of plerixafor did not affect the purity of further TCR-alpha/beta depletion. Side effects were mild to moderate and consisted of nausea and vomiting.CONCLUSION:
Thus, the safety and high efficacy of plerixafor was proven in healthy pediatric allogeneic hematopoietic cell donors.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Benzilaminas
/
Células-Tronco Hematopoéticas
/
Fator Estimulador de Colônias de Granulócitos
/
Receptores de Antígenos de Linfócitos T alfa-beta
/
Transplante de Células-Tronco Hematopoéticas
/
Mobilização de Células-Tronco Hematopoéticas
/
Ciclamos
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article